The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. Issue 9 (2nd September 2018)

• Record Type: Journal Article
• Authors: Rizzello, Fernando; Mazza, Marta; Salice, Marco; Calabrese, Carlo; Calafiore, Andrea; Campieri, Massimo; Gionchetti, Paolo
• Is Part Of: Expert opinion on drug safety. Volume 17:Issue 9(2018)
• Page Start: 963
• Page End: 969
• Publication Date: 2018-09-02
• Subjects: Inflammatory bowel disease -- ulcerative colitis -- steroids -- beclomethasone dipropionate -- safety -- adverse events; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2018.1510914
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : Beclomethasone dipropionate (BDP) is a second-generation corticosteroid that uses novel drug technologies to ensure colonic targeting and potentially reducing systemic corticosteroid concentrations. It is approved for treatment of patients with mild-to-moderate ulcerative colitis (UC) who do not respond to mesalazine. The gut-selective mechanism of action has the potential to improve the safety profile of BDP compared with other conventional corticosteroids. Areas covered : We reviewed the mechanism of action, efficacy, and safety of BDP in the treatment of UC. The positioning of BDP in management algorithms is also discussed. Expert opinion : The highly selective mechanism of action of BDP restricts the steroid-related side effects. BDP is efficacious in the treatment of active UC. Topical formulation is the first choice in distal UC, while oral formulation is used in patients with an extensive involvement of the colon. The rates of adverse events (AE), serious AEs, and steroid-related side-effects are similar to placebo and mesalamine and slightly inferior to traditional corticosteroids.